While Japanese pharmaceutical companies dominate the list of Asia-Pacific regional innovation pharmaceutical companies announced by Clarivate Analytics recently, Hanmi Pharmaceutical is in a tight race with Japanese companies.
According to Clarivate's analysis, Japanese pharmaceutical companies accounted for nine out of the top 10 innovative pharmaceutical companies in the APAC region. Hanmi Pharmaceutical, which ranked No. 1 in South Korea, marked 11th in the Asia-Pacific region.
In the analysis based largely on three indicators, Hanmi Pharmaceutical's initial-stage partnering score was the same as Japan's Otsuka Holdings, which ranked fifth in the total score standings with 325, and the figure is higher than Japanese firms such as Shionogi, Ono, Mitsubishi Chemical and Kirin Holdings.
Clarivate said it was the pharmaceutical company's comprehensive "R&D capability" that combined "initial stage partnering" and "new drug development" indicators, and Hanmi Pharmaceutical's two figures combined were 620 points, higher than Mitsubishi Chemical and Kirin Holdings.
"Hanmi Pharmaceutical, which scored the best among Korean pharmaceutical companies, performed well in all three indicators," a Clarivate executive said, adding, "We expect Korean pharmaceutical companies, including Hanmi Pharmaceutical, to lead innovation in the pharmaceutical industry in the Asia-Pacific region based on the government's support policy."
"The challenge and innovation of Hanmi Pharmaceutical to develop new drugs in the global market will be evaluated objectively by a trusted institution," said Kwon Se-chang, CEO of Hanmi Pharmaceutical. "We will do our best to create new innovative drugs while closely managing possible situations in the process of developing new drugs.
Clarivate is a global academic information provider through bio-science solutions CortellisTM, the Derwent World Patents IndexTM, the Derwent Patent Citation IndexTM, and the Web of Science.